{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:30:49Z","timestamp":1783344649173,"version":"3.54.6"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40273-022-01227-6","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T01:02:21Z","timestamp":1672189341000},"page":"307-319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen\u00a0for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU\u00a0Chemotherapy"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-2586","authenticated-orcid":false,"given":"Chen-Han","family":"Chueh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-7217","authenticated-orcid":false,"given":"Yi-Wen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4777-6792","authenticated-orcid":false,"given":"Zi-Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-3696","authenticated-orcid":false,"given":"Ming-Neng","family":"Shiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-3845","authenticated-orcid":false,"given":"Yu-Wen","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9292-0055","authenticated-orcid":false,"given":"Nai-Jung","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"issue":"9","key":"1227_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1227_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.20517\/2394-5079.2018.46","volume":"4","author":"V Cardinale","year":"2018","unstructured":"Cardinale V, Bragazzi MC, Carpino G, Matteo SD, Overi D, Nevi L, et al. Intrahepatic cholangiocarcinoma: review and update. Hepatoma Res. 2018;4:20.","journal-title":"Hepatoma Res."},{"key":"1227_CR3","unstructured":"Health Promotion Administration, Ministry of Health and Welfare, Taiwan. Cancer Registry Annual Report, 2019. Taipei: Health Promotion Administration, Ministry of Health and Welfare, Taiwan; 2021."},{"issue":"11","key":"1227_CR4","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","volume":"18","author":"F Farshidfar","year":"2017","unstructured":"Farshidfar F, Zheng S, Gingras M-C, Newton Y, Shih J, Robertson AG, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017;18(11):2780\u201394.","journal-title":"Cell Rep"},{"key":"1227_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/PO.18.00414","volume":"4","author":"J Cao","year":"2020","unstructured":"Cao J, Hu J, Liu S, Meric-Bernstam F, Abdel-Wahab R, Xu J, et al. Intrahepatic cholangiocarcinoma: genomic heterogeneity between Eastern and Western patients. JCO Precis Oncol. 2020;4:557\u201369.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"1227_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","volume":"73","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer. J Hepatol. 2020;73(1):170\u201385.","journal-title":"J Hepatol"},{"issue":"5","key":"1227_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384.","journal-title":"Lancet Oncol"},{"issue":"14","key":"1227_CR8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"5","key":"1227_CR9","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690\u2013701.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1227_CR10","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","volume":"22","author":"C Yoo","year":"2021","unstructured":"Yoo C, Kim K-P, Jeong JH, Kim I, Kang MJ, Cheon J, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 2021;22(11):1560\u201372.","journal-title":"Lancet Oncol"},{"key":"1227_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100337","volume":"27","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Brandi G. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun. 2021;27: 100337.","journal-title":"Cancer Treat Res Commun."},{"key":"1227_CR12","unstructured":"National Institute for Health and Care Excellence (NICE). Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [Technology appraisal guidance TA722]. London: NICE; 2021."},{"key":"1227_CR13","doi-asserted-by":"crossref","unstructured":"Reimbursement Team. Pemigatinib (Pemazyre). Can J Health Technol. 2022;2:4.","DOI":"10.51731\/cjht.2022.303"},{"issue":"6","key":"1227_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40273-021-01112-8","volume":"40","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics. 2022;40(6):601\u20139.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1227_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10\u201331.","journal-title":"Value Health."},{"issue":"12","key":"1227_CR16","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","volume":"23","author":"BS Woods","year":"2020","unstructured":"Woods BS, Sideris E, Palmer S, Latimer N, Soares M. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now? Value Health. 2020;23(12):1613\u201321.","journal-title":"Value Health."},{"issue":"1","key":"1227_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12962-019-0182-7","volume":"17","author":"MA Pahuta","year":"2019","unstructured":"Pahuta MA, Werier J, Wai EK, Patchell RA, Coyle D. A technique for approximating transition rates from published survival analyses. Cost Eff Resour Alloc. 2019;17(1):12.","journal-title":"Cost Eff Resour Alloc."},{"key":"1227_CR18","unstructured":"Rohatgi A. WebPlotDigitizer. 2021. https:\/\/automeris.io\/WebPlotDigitizer\/. Accessed 30 Jun 2022."},{"issue":"12","key":"1227_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"1","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;1(12):9.","journal-title":"BMC Med Res Methodol"},{"key":"1227_CR20","unstructured":"Mohammed S. Introduction to survival analysis using R. Workshop on Computational Biostatistics and Survival Analysis. 2022. https:\/\/shariq-mohammed.github.io\/files\/cbsa2019\/1-intro-to-survival.html. Accessed 3 Jul 2022."},{"key":"1227_CR21","unstructured":"Sestelo M. 3.6 How to evaluate the PH assumption? A short course on survival analysis applied to the financial industry. In: Madrid: BBVA Data & Analytics; 2017."},{"issue":"2","key":"1227_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0037","volume":"4","author":"D Su","year":"2021","unstructured":"Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021;4(2): e210037.","journal-title":"JAMA Netw Open"},{"key":"1227_CR23","unstructured":"National Institute for Health and Care Excellence (NICE). Sorafenib for treating advanced hepatocellular carcinoma [technology appraisal guidance TA474]. London: NICE; 2017."},{"key":"1227_CR24","unstructured":"Chiang N-J, Tan KT, Zhuo D-W, Chen M-H, Chen S-J, Chiu T-J, et al. Comprehensive genomic profiling of 157 Taiwanese intrahepatic cholangiocarcinoma and its correlation with survival [poster presentation]. In: The 25th Taiwan Joint Cancer Conference; 4-5 September, 2021; Taipei."},{"issue":"4","key":"1227_CR25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3747\/co.23.2244","volume":"23","author":"J Amdahl","year":"2016","unstructured":"Amdahl J, Diaz J, Park J, Nakhaipour HR, Delea TE. Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. Curr Oncol. 2016;23(4):340\u201354.","journal-title":"Curr Oncol"},{"key":"1227_CR26","unstructured":"National Institute for Health and Care Excellence (NICE). Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib [technology appraisal guidance TA427]. London: NICE; 2017."},{"key":"1227_CR27","unstructured":"ACT Genomics. ACTFusion\u2122. 2022. https:\/\/www.actgenomics.com\/professional_product.php?id=3. Accessed 20 Oct 2022."},{"issue":"1","key":"1227_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/heapol\/czw096","volume":"32","author":"LA Robinson","year":"2017","unstructured":"Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017;32(1):141\u20135.","journal-title":"Health Policy Plan"},{"key":"1227_CR29","unstructured":"World Health Organization. Office of World Health R. The world health report: 2002: reducing risks, promoting healthy life: overview. Geneva: World Health Organization; 2002."},{"issue":"4","key":"1227_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, Van Voorn GAK, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349\u201361.","journal-title":"Pharmacoeconomics"},{"key":"1227_CR31","unstructured":"National Institute for Health and Care Excellence (NICE). Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations [ID3730]. Committee papers. London: NICE; 2021."},{"issue":"10","key":"1227_CR32","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1080\/13696998.2020.1796360","volume":"23","author":"H Cranmer","year":"2020","unstructured":"Cranmer H, Shields GE, Bullement A. A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology. J Med Econ. 2020;23(10):1176\u201385.","journal-title":"J Med Econ"},{"key":"1227_CR33","unstructured":"Center for Drug Evaluation, Taiwan (CDE). Methodology guide for health technology assessment. Taipei: CDE; 2013."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01227-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-022-01227-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01227-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T12:43:57Z","timestamp":1676378637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-022-01227-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1227"],"URL":"https:\/\/doi.org\/10.1007\/s40273-022-01227-6","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,28]]},"assertion":[{"value":"17 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nai-Jung Chiang has received payment for lectures from Eli Lilly and Company, TTY Biopharm Company Limited, Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, PharmaEngine, Inc., and Roche. Chen-Han Chueh, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, and Yi-Wen Tsai have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The Institutional Review Board of National Yang\u00a0Ming\u00a0Chiao Tung \u00a0University, Taiwan approved this study (YM111012E).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The data that support the findings of this study are available from the Ministry of Health and Welfare, Taiwan, but restrictions apply to the availability of these data, which were used under license for the current study and are not publicly available.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The Institutional Review Board of National Yang Ming Chiao Tung University (IRB) agreed to waive the consent to participate for this research because this research is low risk. Furthermore, the possible risk to the research subjects is no more than that of those who did not participate in the research, and the exemption from obtaining prior consent does not affect the rights and interests of the research subjects.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Consent to publish is not required because the IRB agreed that this research did not require consent to participate.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The code supporting the findings of this study is available from the corresponding authors upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: Y-WW, Y-WT, N-JC; data curation: Z-RC; formal analysis: C-HC, Z-RC; methodology: M-NS, Y-WW, Y-WT; project administration: M-NS, Y-WT, N-JC; resources: Y-WT; software: C-HC, Z-RC; supervision: M-NS, Y-WW, Y-WT, N-JC; validation: C-HC; visualization: C-HC, Z-RC; writing, original draft: C-HC, Z-RC, Y-WT; writing, review and editing: C-HC, M-NS, Y-WW, Y-WT, N-JC. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}